Questions | Multiple-choice responses | All, n (%) | H CPR, n (%) | M CPR, n (%) | L CPR, n (%) |
N=75 | N=17 | N=51 | N=7 | ||
1. Do you have any preference in the schedule of ICI choice for the treatment of CPs? | ☐ Yes, I prefer the schedule with the shorter interval | 31 (41.3) | 9 (52.9) | 21 (41.2) | 1 (14.3) |
☐ Yes, I prefer the schedule with the longer interval | 39 (52) | 7 (41.2) | 26 (51) | 6 (85.7) | |
☐ No, the schedule interval is not a criteria for ICI choice in my clinical practice | 5 (6.7) | 1 (5.9) | 4 (7.8) | 0 (0) | |
2. Do you have currently (during COVID-19 pandemic) any preference in the schedule of ICIs for the treatment of CPs? | ☐ Yes, I prefer the schedule with the shorter interval | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
☐ Yes, I prefer the schedule with the longer interval | 58 (77.3) | 13 (76.5) | 38 (74.5) | 7 (100) | |
☐ No, the schedule interval is not a criteria for ICI choice in my current clinical practice | 17 (22.7) | 2 (23.5) | 13 (25.5) | 0 (0) | |
3. Have you modified the dose of steroids you give in case of ICI adverse events? | ☐ Yes, I have reduced the dose | 3 (4) | 1 (1.9) | 1 (2) | 1 (14.3) |
☐ No, I continue to follow the recommendation for the AE management | 72 (96) | 16 (94.1) | 50 (98) | 6 (85.7) | |
4. Has the COVID-19 pandemic changed your treatment choice for CP-ICI in case of alternative treatments like chemotherapy, where applicable, as for clinical practice guidelines? | ☐ Yes | 6 (8) | 1 (5.9) | 5 (9.8) | 0 (0) |
☐ No | 69 (92) | 16 (94.1) | 46 (90.2) | 7 (100) | |
5. Has the COVID-19 pandemic changed your treatment choice for CP-ICI in case of alternative treatments like targeted therapy, where applicable, as for clinical practice guidelines? | ☐ Yes | 9 (12) | 2 (11.8) | 6 (11.8) | 1 (14.3) |
☐ No | 66 (88) | 15 (88.2) | 45 (88.2) | 6 (85.7) | |
6. Are the CP-ICI preferentially seen in COVID-19 clear institutions? | ☐ Yes | 29 (38.7) | 6 (35.3) | 21 (41.2) | 2 (28.6) |
☐ No | 46 (61.3) | 11 (64.7) | 30 (58.8) | 5 (71.4) | |
7. Do you use G-CSF in case of CP-ICIs with no febrile neutropenia (when used ±chemotherapy)? | ☐ Yes | 12 (16) | 1 (5.9) | 11 (21.6) | 0 (0) |
☐ No | 63 (84) | 16 (94.1) | 40 (78.4) | 7 (100) | |
8. Has this decision been changed by the COVID-19 pandemic? | ☐ Yes | 6 (8) | 2 (11.8) | 4 (7.8) | 0 (0) |
☐ No | 69 (92) | 15 (88.2) | 47 (92.2) | 7 (100) | |
9. Have the CP-ICI been managed in expert centers for immunotherapy? | ☐ Yes | 53 (70.7) | 15 (88.2) | 34 (66.7) | 4 (57.1) |
☐ No | 22 (29.3) | 2 (11.8) | 17 (33.3) | 3 (42.9) | |
10. Has this decision been changed by the COVID-19 pandemic? | ☐ Yes | 1 (1.3) | 0 (0) | 1 (2) | 0 (0) |
☐ No | 74 (98.7) | 17 (100) | 50 (98) | 7 (100) | |
11. Do you prefer to delay ICI start in lung cancer patients because of potential lung toxicity considering the high lung tropism of SARS-CoV-2 virus and its risk of ARDS? | ☐ Yes | 8 (10.7) | 3 (17.6) | 4 (7.8) | 1 (10.7) |
☐ No | 67 (89.3) | 14 (82.4) | 47 (92.2) | 6 (85.7) | |
12. In your institution, has surgery for CP been delayed because of the COVID-19 pandemic? | ☐ Yes | 35 (46.7) | 9 (52.9) | 24 (47.1) | 2 (28.6) |
☐ No | 40 (53.3) | 8 (47.1) | 27 (52.9) | 5 (71.4) |
H CPR: high (H) prevalence regions with more than 10,000 positive patients, M CPR: medium (M) prevalence regions with positive patients less than 10,000 and more than 4000, L CPR: low (L) prevalence regions with less than 4000 positive patients.
ARDS, acute respiratory distress syndrome; CP, cancer patient; CP-ICI, cancer patients undergoing or candidate for immune checkpoint inhibitor; ICI, immune checkpoint inhibitor; N, number.